Novavax to Join 2024 Jefferies Healthcare Conference

GAITHERSBURG, Md., May 30, 2024 — Novavax, Inc. (Nasdaq: NVAX), a leading global company in the field of protein-based vaccines enhanced with its Matrix-M™ adjuvant, has confirmed its participation in the upcoming 2024 Jefferies Global Healthcare Conference.

The conference will feature a recorded fireside session with Novavax, and the replay of this session will be accessible on the Events & Presentations page of the Company’s website at ir.novavax.com for a period of 30 days following the event.

Company Overview

Novavax, Inc., headquartered in Gaithersburg, Maryland, is dedicated to advancing global health through the development, discovery, and commercialization of innovative vaccines that offer protection against severe infectious diseases. The company utilizes a distinctive vaccine platform, which integrates a recombinant protein approach with innovative nanoparticle technology and the proprietary Matrix-M adjuvant to bolster the immune response. 

Key Products and Pipeline

Novavax’s product portfolio is spearheaded by its COVID-19 vaccine. Additionally, the company’s pipeline includes promising candidates such as a combination COVID-19-Influenza vaccine and a standalone influenza vaccine. Notably, the Matrix-M adjuvant from Novavax is also a critical component of the R21/Matrix-M malaria vaccine developed in collaboration with the University of Oxford and Serum Institute of India.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!